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Abstract

Objectives. The objective of this study was to explore the impact of specific cost formats on individuals’
decision making.

Methods. Mechanical Turk workers completed a choice based conjoint (CBC) analysis survey designed to
examine preferences for three second line agents used to treat diabetes: a sulfonylurea, exenatide, and
insulin. Diabetes was chosen because the disease is familiar to the general public and people are generally
aware of the importance of controlling blood sugar levels. The CBC survey included five attributes: route of
administration, efficacy, risk of low blood sugar, frequency of checking blood sugar levels and cost. We
developed seven versions of the CBC survey which were identical except for the cost attribute. We described
cost in terms of: Affordability, Monthly Co-pay, Dollar Sign Rating, How Expensive or How Cheap compared to
other medications, Monthly Co-pay, Working Hours Equivalent (per month) and Percent of Monthly Income.
The resulting part-worth utilities were used to calculate the relative importance of cost and to estimate
treatment preferences.

Results: Cost had the greatest influence on participants’ decisions when framed in terms of Affordability and
the lowest influence when framed in terms of How Cheap (compared to other drugs). Sulfonylurea is strongly
preferred across Affordability, Percentage of Monthly Income, Monthly Copay and Dollar Sign formats.
Exenatide is preferred when cost is described using the How Cheap and How Expensive format.

Conclusions. How to frame cost impacts subjects’ medical decision remarkably. Patients will be the most costsensitive when cost is framed in terms of affordability, the least cost-sensitive when considering how cheap the
medication is compared to others. Further researches are needed to evaluate the impact of presentation of
cost on decision making in clinical contexts.
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Table 1. Attributes and levels included in the CBC survey

Versions

Levels

Route of administration

1 pill twice a day
Injection (shot) under the skin once a day

Efficacy

Mildly effective (usually need another medication)
Moderately effective (may need another medication)
Extremely effective (this medication is enough)

Risk of low blood sugar

1% risk
20% risk
30% risk

Frequency of checking blood sugar
levels

No monitoring necessary
3 times per week
1 time per day

Cost
Affordability

Easily affordable
Somewhat affordable
Hard to afford

Monthly Co-pay

$15 for a one month’s supply
$120 for a one month’s supply
$350 for a one month’s supply

Dollar Sign Rating

$
$$
$$$

How Expensive

This medicine is not more expensive compared to others
This medicine is somewhat more expensive compared to others
This medicine is much more expensive compared to others

How Cheap

This medicine is much cheaper compared to others
This medicine is somewhat cheaper compared to others
This medicine is not cheaper compared to others

Percentage of Monthly Income

0.6% of monthly income for a one month's supply
5% of monthly income for a one month's supply
15% of monthly income for a one month's supply

Working Hours Equivalent

1 hour of work for a one month's supply
1 day of work for a one month's supply
3 days of work for a one month's supply

Table 2. Description of the sample according to the group of participators a
Randomized versions
Affordability
(N=176)b

Monthly Copay (N=162)b

Dollar Sign
Rating
(N=169)b

How Cheap
(N=165)b

How
Expensive
(N=170)b

Percentage
of Monthly
Income
(N=169)b

Working
Hours
Equivalent
(N=152)b

pc

Age (years)

36.7 ± 12.6

35.0 ± 11.7

34.8 ± 11.8

34.2 ± 11.2

35.4 ± 11.7

36.4 ± 11.7

34.4 ± 9.7

0.31

Female

79 (44.9%)

77 (47.5%)

90 (53.3%)

89 (53.9%)

86 (50.6%)

81 (47.9%)

74 (48.7%)

0.64

Characteristic

Education level
Some high school

0.30
0 (0.0%)

2 (1.2%)

4 (2.4%)

1 (0.6%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

High school graduate

23 (13.1%)

22 (13.6%)

18 (10.7%)

15 (9.1%)

17 (10.0%)

21 (12.4%)

13 (8.6%)

Some college

63 (35.8%)

48 (29.6%)

55 (32.5%)

58 (35.2%)

51 (30.0%)

56 (33.1%)

50 (32.9%)

College graduate or more

90 (51.1%)

90 (55.6%)

92 (54.4%)

91 (55.2%)

102 (60.0%)

92 (54.4%)

89 (58.6%)

Annual Income > $25,001

102 (58.0%)

103 (63.6%)

113 (66.9%)

95 (57.6%)

99 (58.2%)

114 (67.5%)

99 (65.1%)

0.22

Has health insurance

142 (80.7%)

131 (80.9%)

135 (79.9%)

146 (85.9%)

144 (87.3%)

144 (85.2%)

124 (81.6%)

0.39

Diabetic

10 (5.7%)

10 (6.2%)

8 (4.7%)

8 (4.9%)

10 (5.9%)

10 (5.9%)

5 (3.3%)

0.92

Takes medication(s) regularly

64 (36.4%)

48 (29.6%)

56 (33.1%)

53 (32.1%)

57 (33.5%)

59 (34.9%)

61 (40.1%)

0.58

Cost influences decision to try
a medication

0.68

Never

18 (28.1%)

14 (29.2%)

15 (26.8%)

11 (20.8%)

14 (24.6%)

14 (23.7%)

14 (23.0%)

Often

33 (51.6%)

27 (56.3%)

27 (48.2%)

31 (58.5%)

25 (43.9%)

35 (59.3%)

37 (60.7%)

Always

13 (20.3%)

7 (14.6%)

14 (25.0%)

11 (20.8%)

18 (31.6%)

10 (17.0%)

10 (16.4%)

a

Table values are mean ± SD for continuous variables and n (column %) for categorical variables.

b

Percentages may not sum to 100% due to rounding.

c

P-value is for F-test (continuous variables) or χ2 test (categorical variables).

d Questions

were answered only by participators who takes medication(s) regularly.

Table 3. Relative importance of each attribute across the seven cost formats
Cost Format
Attributes
Affordability

Monthly Copay

Dollar Sign
Rating

How Cheap

How
Expensive

Percentage
of Monthly
Income

Working
Hours
Equivalent

pf

Route of administration

11.3 ± 0.9 a

13.1 ± 1.0 a, b

10.5 ± 0.9 a

15.4 ± 1.0 b

12.4 ± 0.9 a

12.4 ± 0.9 a

12.2 ± 1.0 a

0.01

Efficacy

22.7 ± 1.0 d

27.7 ± 1.0 b, c

32.5 ± 1.0 a

30.1 ± 1.0 a, b

31.5 ± 1.0 a

25.4 ± 1.0 c

31.6 ± 1.0 a

<.0001

Risk of low blood sugar

23.1 ± 0.9 c

19.7 ± 1.0 d

23.5 ± 1.0 c

33.8 ± 1.0 a

28.3 ± 1.0 b

22.8 ± 1.0 c

28.9 ± 1.0 b

<.0001

Frequency of checking
blood sugar levels

5.7 ± 0.4 c

6.7 ± 0.4 b, c

7.1 ± 0.4 b

8.7 ± 0.4 a

8.8 ± 0.4 a

6.5 ± 0.4 b, c

6.5 ± 0.4 b, c

<.0001

37.3 ± 0.9 a

32.8 ± 0.9 b

26.3 ± 0.9 c

12.1 ± 0.9 e

19.1 ± 0.9 d

33.0 ± 0.9 b

20.8 ± 1.0 d

<.0001

Cost
a, b ,c , d, e
f

LS Means with the same letter are not significantly different.

P-value is for F-test.

Table 4. Description of medications used to estimate preferences
Route of
administration

Efficacy

Insulin

Injection (shot) under
the skin once a day

Extremely effective (this
medication is enough)

Sulfonylurea

1 pill twice a day

Exenatide

1 pill twice a day

Medications

Moderately effective
(may need another
medication)
Moderately effective
(may need another
medication)

Risk of low
blood sugar

Frequency of checking
blood sugar levels

Cost

30% risk

1 time per day

Level 2 (Medium)

20% risk

3 times per week

Level 1 (Low)

1% risk

No monitoring
necessary

Level 3 (High)
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Introduction
Numerous studies have found that out-of-pocket cost strongly influences patients’
decision-making. Goldman et al 1 and Cole et al 2 found that a 10% increase in cost sharing is
associated with 1-6% reduction in patients’ prescription drug spending and decreased
medication adherence. Shapiro et al 3 showed that patients participating in a cost-sharing
program were less likely to seek medical care for minor symptoms and to be hospitalized for
more serious symptoms compared to those receiving free care. Patients also consider cost
when comparing available treatment options. Tseng et al 4 found that of 5,085 diabetic patients
across 10 health plans, at least two-thirds were willing to consider lower cost medications with
less efficacy, more frequent dosing, or a slightly higher chance of side effects. Despite the
significant impact of cost on patient decision-making, medication expense is rarely discussed
during medical encounters 5,6 and, in general, physicians feel uncomfortable discussing costs
with their patients 7,8. Compounding the problem is that specific costs vary widely and are often
difficult to access 9.
The increasing awareness of cost as a possible treatment harm has led to a call to
recognize cost as a specific attribute that should be weighed in parallel with other treatment
characteristics 10–12. This stance is compatible with recent studies demonstrating that most
patients want to know about out-of-pocket costs and feel comfortable discussing cost with their
physicians 13. However, little is known about how best to describe cost and whether different
cost formats influence patient decision making. Blumenthal-Barby et al 14 found that cost-related
data were mentioned in 56% of the patient decision aids using nine different approaches.
However, whether and how varying formats influenced decision making was not examined.
In order to address this gap in knowledge, we designed an experimental study to explore
the impact of specific cost formats on individuals’ decision making. We used an online choicebased conjoint (CBC) survey to quantify how the presentation of cost information influences the

importance that individuals attach to out-of-pocket costs and to their preferences for specific
treatment options. CBC is a widely used method to elicit preferences that has been shown to
yield valuable insights across many health-related scenarios 15,16. Participants’ preferences are
measured by their choices on a set of hypothetical options described by a predefined list of
attributes. Responses generate a set of part-worth utilities that can be used to calculate the
relative importance of each attribute and to predict preference for specified treatment options.
The survey was designed to elicit preferences for a range of medications used to treat
diabetes mellitus. Diabetes was chosen because the disease is familiar to the general public
and people are generally aware of the importance of controlling blood sugar levels. We
developed seven versions of the survey which were identical except for the format used to
describe out-of-pocket cost. Given the known influence of format on patients’ choices, we
hypothesized that the relative importance of cost and treatment preferences will vary by format.
Methods
Subjects
We recruited 1500 participants from Amazon's Mechanical Turk (MTurk). MTurk is an
online labor market. Its population is more demographically diverse than standard internet
samples 17. Participants on MTurk are internally motivated and produce psychometrically sound
data 18,19. While, not representative of a patient population, MTurk is a valuable approach to
examine the impact of manipulating factors using experimental designs. We included subjects
currently living in U.S who were at least 20 years old. Participants were paid $1.00.
Survey
We developed an educational overview of diabetic medication management, and an
explanation of each of the attributes and levels included in the survey, using Qualtrics (see
Appendix). At the end of the educational component, we provided subjects with a link to access

one of the seven versions of the CBC survey using random assignment. Randomization was
conducted by Qualtrics.
The CBC survey was designed, conducted and analyzed with Sawtooth Software,
Choice Based Conjoint, Version 8.4.3. The survey included five attributes (see Table 1). Three
levels were used in all attributes except for route of administration. The attributes were selected
based on the content of a previously published decision aid 20. We developed seven versions of
the CBC survey. All seven versions were identical except for the cost attribute. We described
cost in terms of: Affordability, Monthly co-pay, Dollar Sign Rating, How Expensive compared to
other medications, How Cheap compared to other medications, Monthly Co-pay, and Working
Hours Equivalent (per month) and Percent of Monthly Income (Table 1). The levels for Working
Hours Equivalent and Percent of Monthly Income were defined based on WHO reports on
affordability of medications and the median net compensation U.S. per capita 21,22.
Participants were asked to respond to 12 CBC choice sets, each including three options.
A “None” option was not included. An example of a choice set is provided Figure 1. We used the
software’s complete enumeration strategy to construct the 12 choice sets. This approach
ensures that 1) each level is shown as few times as possible in a single task; 2) each level is
shown approximately an equal number of times across the choice tasks; and 3) the level of one
characteristic is chosen independently of the levels of other characteristics, so that each
characteristic level's effect can be reliably estimated. The program was set to generate a design
for 300 versions of the CBC survey in each group. The standard error for each level was 0.02
and the efficiencies reported were all 1.000. In addition to the 12 random CBC choice sets, two
fixed tasks with a clear advantageous option were set to check participants’ attention. After the
respondents completed the CBC survey, we collected data on participants’ age, gender,
income, education level, history of chronic medication use, occupation and whether or not they
had diabetes.
Statistical Analysis

For each respondent, part-worth utilities (zero-centered values) were calculated for each
level of each attribute using Hierarchical Bayes (HB) modeling (Sawtooth CBC/HB system for
hierarchical Bayes estimation version 8.4.6). The part-worth utilities are interval data. HB
modeling has the advantage that it can better incorporate heterogeneity between respondents’
choices 23. In HB modeling, the sample averages (prior information) are used to update the
individual utilities in a number of iterations until the sample averages stop changing between
iterations. After this convergence, the cycle is run several thousand more times and the
estimates of each iteration are saved and averaged. We rescaled the utilities on a scale of 0 to
1, using the highest cost level as the reference (0) and the highest utility across all formats as 1.
We calculated the percentage of importance that respondents assigned to each attribute
by dividing the range of part-worth utilities for each attribute by the sum of the ranges and
multiplying by 100. We used Sawtooth Software Market Research Tools (SMRT) to estimate
preferences for three potential second line medications for type 2 diabetes 24: insulin, a
sulfonylurea, and exenatide. For this simulation, a sulfonylurea was assigned the lowest level,
insulin the middle level, and exenatide the most expensive level across cost formats. The levels
assigned to each of these treatment options are provided in Table 4. We also used SMRT to
illustrate participants’ price sensitivity for preferring insulin over exenatide as monthly co-pays
for exenatide were decreased from $350 to $15 per month while holding the cost of insulin at
$120 per month.
We excluded subjects who did not answer either of the attention-check questions
correctly: 48 participants failed to answer both attention-check questions correctly and 122
failed to answer one correctly. We subsequently excluded an additional 77 participants who
completed the survey in less than 3.5 minutes (the 5th percentile). Preference data were
imported into SAS Version 9.3 and merged with the respondents’ characteristics. We compared
participants’ characteristics across the seven versions, using the chi-square test for categorical
data and ANOVA for continuous data. We compared the relative importance of the cost attribute

across the seven formats using ANOVA and Tukey’s method to correct for multiple
comparisons. The study was approved by the Human Investigation Committed at our institution.
Results
Participants
1163 eligible participants were included in the final analyzes. Participants’ age ranged
from 18 to 73 years, with a mean of 35.3 years (SD, 11.5 years). Most participants had finished
high school (99.5%), 37.6% earned less than $25,000 per year, and 34.2% took medication
regularly. Characteristics were similar across the seven versions of the CBC survey (Table 2).
Cost Utilities and Relative Importance
Figure 2 plots the rescaled utilities for each level of cost across the seven formats.
Lowering cost from the high to medium level had a larger impact compared to lowering cost
from the medium to lowest level for all formats. This difference was most evident for the
Affordability and Percent of Monthly Income formats. Increasing cost from the lowest to the
medium level had the greatest impact in the Monthly Co-pay and Percent of Monthly Income
formats.
The relative importance of cost differed significantly across the seven cost formats
(Table 3, Figure 3). Cost had the greatest influence on participants’ decisions when framed in
terms of Affordability, with the relative importance of cost in this version being significantly
higher than in the remaining six. In contrast, cost had the least influence on participants’
decisions when framed as How Cheap. Cost was the most influential of the five attributes when
framed in terms of Affordability, Monthly Co-pay or Percentage of Monthly Income.
Treatment Preferences
Predicted preferences for insulin, exenatide, and a sulfonylurea are described in Figure
4. A sulfonylurea is strongly preferred option across four of the cost formats. Exenatide is
preferred when cost is described using the How Cheap format. In this format, the risk of low

blood sugar is the most important attribute (Table 3), and it is substantially lower with exenatide
than a sulfonylurea. A similar pattern is seen with the How Expensive format. Preference for
insulin, the most effective, albeit the riskiest option, is low across all cost formats.
Figure 5 reveals the estimated preferences for insulin (Held fixed at $120 per month)
over exenatide as out-of-pocket costs of exenatide are decreased from $350 to $15 per month.
When described in terms of Percent of Monthly Income or Monthly Co-pay, preference for
insulin supersedes that of exenatide once the cost of insulin is decreased to $60 or less per
month. When described in terms of Working Hours Equivalent, insulin is never preferred over
exenatide, even at the lowest copays.
Discussion
In this study, we explored whether and how varying cost presentation formats influence
individuals’ decision making. Our results demonstrated that the relative importance of cost and
treatment preference are sensitive to the manner in which cost is described. We found that cost
had the largest impact when described in terms of Affordability and the lowest impact when
described in terms of How Cheap the medication is compared to other options. Affordability may
have had the largest impact on subjects’ choices because the lowest level “Hard to Afford” may
be especially displeasing. In addition, unlike the formats describing a specific numeric estimate,
“Hard to Afford” is likely to have a negative impact on all subjects, regardless of income level.
Affordability may also be the most evaluable format. According to the evaluability hypothesis,
attributes which are more easily evaluated have a larger impact on choice25. While we were not
surprised to find that the How Cheap format had the smallest influence on subjects’ choices, we
did not expect “This medicine is much more expensive compared to others” to be less
concerning to subjects then several of the other formats. It is possible, that people are
accustomed to medications being expensive, thus perhaps dampening the impact of this format
on subjects’ reactions. Interestingly, subjects were more influenced by cost when described in

terms of Percent of Monthly Income than Working Hours Equivalent despite these two formats
representing equivalent cost estimates. “15%” may have been perceived as larger to subjects
than “3 days” of income. Alternatively, Percent of Monthly Income may be more “evaluable” than
Working Hours Equivalent. Percent of Monthly Income may also have had a greater impact,
since it may have been more easily interpreted as income lost, compared to Working Hours
Equivalent. This explanation would be in keeping with prospect theory’s description of loss
aversion 26,27.
The differences in the impact of cost over the formats studied translated into differences
in preferred treatment options. Despite being less effective and more likely to cause
hypoglycemia than insulin, the sulfonylurea is preferred across four of the seven formats
because they are less costly. Exenatide, the most expensive option, is preferred in the
remaining three formats, most notably when using the How Cheap format. This finding has
potentially important clinical implications, as varying terminology may influence patients in a
manner which could alter treatment decisions. Thus, future research should determine if
alternative formats impact on patients’ decisions in clinical settings.
To the best of our knowledge, this is the first study to explore the impact of varying cost
formats on subjects’ decision making. We used a randomized, between-subjects, experimental
design, which enabled us to isolate the effect of the manipulated variable. In addition, CBC
enabled us to quantify the relative importance of cost as an attribute, to compare differences in
subjects’ reactions to increasing cost from a low to medium level versus a medium to high level,
and to estimate preferences for competing treatment options. There are also several limitations
of the study. First, as with other studies using simulated scenarios, stated preferences may not
reflect the actual decision-making process in a clinical setting which involves many other
important issues. Furthermore, although we designed the surveys based on a pre-established
decision-aid for escalation of diabetic care, patients may consider other attributes when making
treatment decisions. In addition, since this study was conducted online using MTurk workers,

most of whom were not taking medications on a regular basis, we were not able to describe
differences between participants and patients with diabetes. Next, this study focused only on the
escalation of diabetes treatment. Further research should examine whether the similar effects
would be observed in other scenarios. Lastly, we hypothesized that evaulability may have
accounted for some of the differences seen. Future studies should test this hypothesis and
explore additional reasons underlying the variability observed in this study.
In summary, we found that the format by which cost is presented has a significant impact
on peoples’ choices. Participants in this study were most cost-sensitive when considering how
affordable a medication is, and least influenced by cost when considering how cheap a
medication is compared to others. When using actual numerical values to describe co-pays,
Working Hours Equivalent hours has less impact than either Monthly Co-pays or Percent of
Monthly Income. Clinicians and researchers should be aware of the potential impact of variable
presentation formats on decision making. These results support the need to evaluate the impact
of presentation of cost on decision making in clinical contexts.
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Appendix
Diabetes is a major health problem in the US. This survey is designed to help us understand
how patients feel about blood sugar medications. Before we start the survey, we will provide you
with some essential information about this disease.

What happens if diabetes isn't well controlled?
People with diabetes have increased levels of sugar in their blood. Over time, diabetes leads to
an increased risk of heart disease, strokes, kidney disease, vision problems and neurologic
disease.

How is diabetes treated?
Blood sugars levels can be controlled with different types of medications. The main side effect
of all of these medications is low blood sugar.

Low blood sugar is a condition that can cause symptoms ranging from sweating and feeling
hungry to passing out, when the blood sugar level is too low. Low blood sugar is treated by
administering sugar either in the form of food (example juice) or if necessary by an infusion.

How do patients make sure their blood sugar is at the correct level?
People with diabetes prick their skin to get a drop of blood. The drop
of blood is put into a blood sugar monitor which displays the blood
sugar level.

This survey is designed to help us understand how patients feel about medications.
Please imagine that you have diabetes and need to choose a medication.
The computer program will show you made-up treatment options for diabetes and then will ask
you to pick the one you prefer. Take your time to read through each question. There are no right
or wrong answers.
Each medication will be described using 5 pieces of information:
1. The way the medication is taken
2. The frequency of checking your blood sugar level
3. How well the medication works
4. Risk of low blood sugar
5. The cost to you
The next few pages will give you some more detail about each of these 5 facts:

There are 2 ways that these medications can be taken:
1. As a pill twice a day: Half are taken in the morning and half in the evening.
2. As an injection (shot) under the skin: You give yourself an injection once a day.

How well the medication works:
The medications will be described as either:
Extremely effective: Extremely effective means that most patients' blood sugar levels decrease
to the ideal range.
Moderately effective: Moderately effective means that most patients' blood sugar levels
decrease significantly. But, some patients will need a second medication to keep their blood
sugar in the ideal range.

Mildly effective: Mildly effective means that while the medication does help decrease blood
sugar levels, almost every patient needs another medication to keep their blood sugar in the
ideal range.

Low blood sugar is a side effect of many diabetes medications. Most diabetes medications
help patients lower their blood sugar to the ideal level, but some of them often go too far and
cause this side effect of lower blood sugar.
Mild symptoms of low blood sugar include feeling sweaty, dizzy, and trembling. If the blood
sugar level is extremely low, people can become sleepy or confused, and may develop blurry
vision and have trouble walking. Medications vary in how frequently diabetes medications
cause this side effect.
3 risk levels of low blood sugar will be shown in this survey.
1. 1% risk: This means that 1% or 1 per 100 people who take this medication experience the
side effect of low blood sugar.
2. 20% risk: This means that 20% or 20 per 100 people who take this medication experience
the side effect of low blood sugar.
3. 30% risk: This means that 30% or 30 per 100 people who take this medication experience
the side effect of low blood sugar.

All patients with diabetes need to check their blood sugar levels regularly. This is done by
pricking your skin to get a drop of blood as shown in the picture. A special monitor then displays
the blood sugar level. Medication doses can then be adjusted based on the blood sugar levels.
How often blood sugar levels need to be checked depends on the medication you take.

Attention: The frequency of checking blood sugar level is different from the frequency of taking
medication.

The survey includes 3 options:

1. No monitoring necessary: This means that no blood sugar level monitoring is required while
taking the medication.
2. 3 times per week: This means that you need to check your blood sugar levels 3 times per
week (every other day) while taking the medication. For
example, you can do it every Monday, Wednesday and
Friday or every Tuesday, Thursday, and Saturday.
3. 1 time per day: This means that you need to check your
blood sugar levels once each day. You can do it in the
morning, afternoon or evening.

7 formats of cost

Affordability
Lastly you will also see some information on the cost of the medication. Here we are talking
about the cost you need to pay out of pocket (whether or not you have insurance).
The survey will include 3 estimates of cost:
1. Easily affordable: This means that you don't need to make any changes in your budget in
order to be able to pay for the medication.
2. Somewhat affordable: This means that you need to make some changes in your budget in
order to be able to pay for the medication.
3. Hard to afford: This means that you need to make major changes in your budget in order to
be able to pay for the medication.
Assume you have no other costs such as a deductible.

Monthly Co-pay
Lastly you will also see some information on the cost of the medication. Here we are talking
about the cost you need to pay out of pocket (whether or not you have insurance).
The survey will include 3 estimates of cost:
1. $350 for a one month’s supply: This means that you need to pay $350 for a one month’s
supply of medication.
2. $120 for a one month’s supply: This means that you need to pay $120 for a one month’s
supply of medication.
3. $15 for a one month’s supply: This means that you need to pay $15 for a one month’s
supply of medication.
Assume you have no other costs such as a deductible.

Dollar Sign
Lastly you will also see some information on the cost of the medication. Here we are talking
about the cost you need to pay out of pocket (whether or not you have insurance).
The survey will include 3 estimates of cost:
1. $$$: This means that you need to pay $350 for a one month’s supply of medication.
2. $$: This means that you need to pay $120 for a one month’s supply of medication.
3. $: This means that you need to pay $15 for a one month’s supply of medication.
Assume you have no other costs such as a deductible.

How Cheap (compared to other medication)
Lastly you will also see some information on the cost of the medication. Here we are talking
about the cost you need to pay out of pocket (whether or not you have insurance).

The survey will include 3 estimates of cost:
1. This medicine is cheaper compared to others
2. This medicine is somewhat cheaper compared to others
3. This medicine is much cheaper compared to others
Assume you have no other costs such as a deductible.

How Expensive (compared to other medication)
Lastly you will also see some information on the cost of the medication. Here we are talking
about the cost you need to pay out of pocket (whether or not you have insurance).
The survey will include 3 estimates of cost:
1. This medicine is not more expensive compared to others
2. This medicine is somewhat more expensive compared to others
3. This medicine is much more expensive compared to others
Assume you have no other costs such as a deductible.

Percentage of Monthly Income
Lastly you will also see some information on the cost of the medication. Here we are talking
about the cost you need to pay out of pocket (whether or not you have insurance).
The survey will include 3 estimates of cost:
1. 15% of monthly income for a one month's supply:
This means that a 1 month’s supply of medication may cost you 15% of monthly income.
2. 5% of monthly income for a one month's supply:
This means that a 1 month’s supply of medication may cost you 5% of monthly income.
3. 1% of monthly income for a one month's supply:
This means that a 1 month’s supply of medication may cost you 1% of monthly income.

Assume you have no other costs such as a deductible.

Working Hours Equivalent
Lastly you will also see some information on the cost of the medication. Here we are talking
about the cost you need to pay out of pocket (whether or not you have insurance).
The survey will include 3 estimates of cost:
1. 3 days of work for a one month's supply:
This means that the cost of one month's supply of medication is the same as what you earn for
3 days of work.
2. 1 day of work for a one month's supply:
This means that the cost of one month's supply of medication is the same as what you earn for
1 day of work.
3. 2 hour of work for a one month's supply:
This means that the cost of one month's supply of medication is the same as what you earn for
1 hour of work.
Assume you have no other costs such as a deductible.

